Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial

被引:95
作者
Bissonnette, R. [1 ]
Nigen, S. [1 ]
Langley, R. G. [2 ]
Lynde, C. W. [3 ]
Tan, J. [4 ]
Fuentes-Duculan, J. [5 ]
Krueger, G. [5 ]
机构
[1] Innovaderm Res Inc, Montreal, PQ, Canada
[2] Dalhousie Univ, Div Dermatol, Halifax, NS, Canada
[3] Lynderm Res Inc, Markham, ON, Canada
[4] Windsor Clin Res, Windsor, ON, Canada
[5] Rockefeller Univ, New York, NY 10021 USA
关键词
ACROSYRINGIUM; PERIODONTITIS; USTEKINUMAB; DERMATITIS; CELLS; HAND; TNF;
D O I
10.1111/jdv.12272
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Palmo-plantar pustular psoriasis (PPPP) and palmo-plantar pustulosis (PPP) are chronic skin diseases with significant impact on quality of life. Objectives The purpose of this study was to study the efficacy of ustekinumab in PPPP and PPP and gain more knowledge on the pathophysiology and the role of the interleukin-23 (IL-23) signalling pathway in these diseases. Methods Thirty-three patients with either PPPP (20) or PPP (13) and seven volunteers with normal palmo-plantar skin were recruited. Patients with PPP or PPPP were randomised (1 : 1) to receive either an anti IL-12/IL-23 antibody (ustekinumab 45 mg) or placebo at day 0 and week 4 with subsequent placebo cross-over to ustekinumab at week 16. The primary endpoint was the proportion of patients randomized to ustekinumab achieving a 50% improvement in the Palmo-Plantar Pustular Area and Severity Index (PPPASI-50) as compared to placebo. Skin biopsies of the palms and soles of normal subjects and patients with PPP or PPPP were performed and analysed by RT-PCR and immunohistochemistry. Results There was no statistically significant difference in the proportion of patients randomised to ustekinumab as compared to those randomised to placebo achieving PPPASI-50 at week 16 for patients with PPPP (10%, 20%; P = 1.000) or PPP (20%, 37.5%; P = 1.000) respectively. Compared to normal subjects an 89-fold increase in IL-17A expression was found in palms/soles of patients with PPPP (P = 0.006) and a 190-fold increase for patients with PPP (P = 0.051). There were no statistically significant changes in cytokine expression at week 16 in the palms and soles of patients with PPP or PPPP. Conclusion Taken together these results suggest that ustekinumab at a dose of 45 mg has limited efficacy in PPPP and PPP. IL-17A may have a more important role than IL-23 in patients with PPPP and PPP. Conclusions are limited by the small sample size of this study.
引用
收藏
页码:1298 / 1305
页数:8
相关论文
共 25 条
  • [1] Palmoplantar pustulosis should not be considered as a variant of psoriasis
    Ammoury, A.
    El Sayed, F.
    Dhaybi, R.
    Bazex, J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (03) : 392 - 393
  • [2] Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis
    Au, Shiu-Chung
    Goldminz, Ari M.
    Kim, Noori
    Dumont, Nicole
    Michelon, Melissa
    Volf, Eva
    Hession, Meghan
    Lizzul, Paul F.
    Andrews, Israel D.
    Kerensky, Todd
    Wang, Andrew
    Yaniv, Shimrat
    Gottlieb, Alice B.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (03) : 179 - 187
  • [3] MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis
    Beklen, A.
    Ainola, M.
    Hukkanen, M.
    Gurgan, C.
    Sorsa, T.
    Konttinen, Y. T.
    [J]. JOURNAL OF DENTAL RESEARCH, 2007, 86 (04) : 347 - 351
  • [4] Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study
    Bhushan, M
    Burden, AD
    McElhone, K
    James, R
    Vanhoutte, FP
    Griffiths, CEM
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2001, 145 (04) : 546 - 553
  • [5] Can we really separate palmoplantar pustulosis from psoriasis?
    Brunasso, A. M. G.
    Massone, C.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (05) : 619 - 621
  • [6] Chalmers R, 2006, COCHRANE DATABASE SY, V1
  • [7] Treatment of Refractory Tumor Necrosis Factor Inhibitor-Induced Palmoplantar Pustulosis: A Report of 2 Cases
    Chu, Derek H.
    Van Voorhees, Abby S.
    Rosenbach, Misha
    [J]. ARCHIVES OF DERMATOLOGY, 2011, 147 (10) : 1228 - 1230
  • [8] Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment tool
    Farley, Elizabeth
    Masrour, Shamin
    McKey, Joanna
    Menter, Alan
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (06) : 1024 - 1031
  • [9] DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE
    FINLAY, AY
    KHAN, GK
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) : 210 - 216
  • [10] Ustekinumab in the treatment of palmoplantar pustulosis
    Gerdes, S.
    Franke, J.
    Domm, S.
    Mrowietz, U.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (05) : 1116 - 1118